Skip to content

Brenntag stock

BNR.DEXETRA

Brenntag SE, Basic MaterialsISIN DE000A1DAHH0WKN A1DAHH

$63.91▼ $2.20 (−3.3%)Closing price of 12 Nov 2026

56Score 56 out of 100, Neutral

Turn on early warning

Price and trend

57 / 100

Price history

+17% in one year

The chart shows daily closes over 17 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.

Long-term trend

Below the 200-day line: the price is 1.3% below it.

Trend change

Since March 2026 the 50-day line has been above the 200-day line; the trend has turned up.

Momentum

Sharply down: the price has fallen very quickly lately (RSI 29).

Distance to the high

The price is 12% below its 52-week high. Largest decline in 17 years: 50% (April 2015 to March 2020).

Chart figures for advanced users
SMA 50$68.34
Average price of the last 50 trading days, shows the short-term trend.
SMA 200$64.76
Average price of the last 200 trading days, shows the long-term trend.
RSI (14)29
Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
MACDbelow the signal line
Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
Support$49.40
The lowest closing price of the last twelve months.
Resistance$72.37
The highest closing price of the last twelve months.
Market cap
$9.55B
Div. yield
3.2%
12 months
23.5
on reported earnings of the last twelve months
14.2
on earnings for the next twelve months ($4.64 per share)
Fair value
$89.79

Snapshot

Computed from the data by fixed rules, no AI

  • Brenntag SE belongs to the Chemicals (Specialty) industry (Germany) and, with a market value of $9.23B, is number 33 of 108 companies in its industry on MEQIRI.
  • In fiscal 2025 it reported revenue of $16.88B (down 6.6% year on year) and earnings of $294.42M (down 50.7%).
  • For fiscal 2026, analysts expect on average revenue of $17.43B (up 3.2%) and adjusted earnings per share of $4.76 (up 135.8%).
Show more
  • MEQIRI Score 56 out of 100 (Neutral): rank 255 of 467 in Basic Materials, median 58.
  • The P/E is 22.7 (Chemicals (Specialty) median 24.4, own median of recent years 19.3).
  • Our model puts fair value at $89.79, with the price 26% below it.

In plain words

The numbers on this page in plain words, written by an AI

Strengths

  • Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 85
  • Earnings turn into cashFree cash flow 141% of earnings over the last 12 months.Fundamentals 85
  • Share buybacksShare count down 7% since 2020.Capital allocation 63

Weaknesses

None of our weakness checks flags anything. Crash risk is measured separately.

56/ 100
MEQIRI Score
Neutral

Its standout strength is fundamentals, while profitability and growth hold the score back.

Daily figure as of 12 Nov 2026

How the score is calculated

Score overview

Score since yesterday from 58 to 56.

Fundamentals are strong, with stable profits and strong cash generation.

Profit consistency100% of years
Cash conversion (free cash flow to earnings, 12 months)141%
ROIC (12 months)6.5%
Positive free cash flow100% of years
How this category is measured

Score history

The full history of up to 20 years comes with MEQIRI Pro.

See plans

Crash risk low

How well MEQIRI warns

One of the 30% with the lowest crash risk among smaller stocks.

From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.

What drives the risk

  • cyclical sector (energy or materials), as a group, crashed more often in the backtest

What lowers it

  • solid fundamentals

Valuation

Valuation signal

Possible value trap
Price
$66.12
Fair value
$89.79
Gap to fair value
−26%

Closing price of 11 Nov 2026, used by the daily score.

In our model the price counts as cheap below $69.07 and expensive above $128.28 (uncertainty medium, based on the price swings of the past year).

The two parts of the fair value come to $111.04 (cash-flow model) and $68.54 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.

Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $80.35, at 6.1% it would be $103.98.

Possible value trap: looks cheap, but weak growth.

Valuation metrics

3.94
9.2
Fair value (model)
$89.79
Earnings part $68.54 (earnings per share $2.81 × 24.4)

Half from the cash-flow model, half from earnings times the industry P/E (24.4).

Calculate with your own assumptions

Company performance

This shows several years of history with an automatic assessment.

Revenue

18 years

In the twelve months to 30 Jun 2026, revenue fell 5.3% on the twelve months before. Revenue has grown solidly since 2008, at about 4% per year.

Margins

18 years
  • Gross margin
  • Operating margin
  • Net margin

In fiscal 2025: gross 13%, operating 5%, net 2%.

Debt & balance sheet

latest quarter
0.81
5.3x
1.7
Cash & equivalents
$566.36M

Moderate debt, and interest is adequately covered.

Earnings

Next earnings
10 Mar 2027in 118 days
Last reported
11 Nov 2026EPS reported $1.01 (expected $1.20)below expectations

Analyst estimates

Earnings estimates have barely changed since 15 Oct 2026.

Fiscal 202615 analysts
Earnings per share
$4.760.0%
Revenue
$17.43B0.0%
Fiscal 202714 analysts
Earnings per share
$4.630.0%
Revenue
$17.42B0.0%

MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.

Company outlook raised

Share price after the results: −3.0%

Guidance raised because of year-to-date outperformance; for the second half, benefits are expected to decrease into the third quarter and to level out at about last year's levels in the fourth quarter.

Supporting passage from the call, verbatim
“So I mean, it's hard to predict what we are actually expecting at this point in time is really what I've said is a decrease of the benefits sequentially month by month into the third quarter and then this to level out at similar levels compared to the previous year in the fourth quarter.”

The outlook is not part of the score and not a recommendation to buy or sell.

From the earnings call on 12 Aug 2026 (fiscal Q2 2026), read by AI.

What happened at Brenntag

The key events of the last six months from our own data. A click takes you to the matching card.

Sector comparison

467 rated companies in Basic Materials

Rank 255 of 467
255/ 467
This company
56
Sector median
58

Categories against the sector median

ProfitabilityMedian of 467 companies34 (median 49)15 below the median
GrowthMedian of 467 companies25 (median 54)29 below the median
FundamentalsMedian of 467 companies85 (median 65)20 above the median
ValuationMedian of 426 companies with a value65 (median 69)4 below the median
StabilityMedian of 467 companies69 (median 67)2 above the median
Capital allocationMedian of 467 companies63 (median 52)11 above the median
Technical analysisMedian of 467 companies57 (median 54)3 above the median
MomentumMedian of 467 companies59 (median 51)8 above the median

The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.

Competitors in Chemicals (Specialty)

The next larger and next smaller companies by market value

All 108 Chemicals (Specialty) stocks

ETFs that hold Brenntag

Held by 131 ETFs on Xetra. Shown per index: the ETF with the largest weight.

ETFWeightCostFund size
Deka DAXplus Maximum Dividend UCITS ETFEL4X5.04%0.30%€252.82M
iShares STOXX Europe 600 Chemicals UCITS ETF (DE)EXV73.11%0.46%€114.14M
Amundi DivDax II UCITS ETF DistE9031.29%0.25%€66.94M
Show 5 more

Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).

Data status and sources

Score
Daily value of 12 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Currency
Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Neutral, published since 7 Nov 2026 (in the score history since 14 Mar 2025)
  • Valuation signal Fairly valued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy